Synovial sarcoma - Is adjuvant treatment of value? A retrospective review of adults and children treated at a single centre

9023 Background Synovial Sarcomas (SS) are rare tumours where the role of adjuvant therapy remains controversial. Our institution has adopted a philosophy of surgery alone for resectable tumours, reserving chemotherapy and/or radiotherapy for marginal, unresectable or metastatic disease. Methods 33 children and adults over a 14 year period. Median age at diagnosis was 27 years (range 7–71). Staging and treatment: stage 1 5cms = 3/7 surgery alone, 4 additional chemotherapy/RXT; stage 2 = 1/6 surgery alone, 5 additional treatment. Stage 3 =1, and stage 4 =6, all had chemotherapy and/or radiotherapy. Radiotherapy doses were50–64 Gy in 25–32 fractions, and chemotherapy was alkylating agent and doxorubicin based. Results Diagnosis increased from 1.55 to 4.75 cases/year after introduction of t(X:18) testing. 92% (12/13) of Stage 1 <5cm remain in first remission (CR1), and 100% (13/13) are currently alive and disease free. In contrast 43% (3/7) with Stage ...